Study drug follow-up for LDL reduction in high-risk cholesterol patients
Treatments studied
Part of Genetic & congenital, Hormones & metabolism clinical trials.
This Phase 3 study looks at the long-term safety and benefit of OLE LIB003 for people with very high cholesterol or heart disease risk who still need lower LDL (“bad cholesterol”). It’s likely a continuation study for participants who already did earlier LIB003 Phase 3 trials.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have successfully completed one of the earlier Phase 3 LIB003 base studies (listed in the criteria) with no study-drug–related serious side effects.
- You must sign consent before any study-specific testing or procedures.
- If you could become pregnant, you must use very reliable birth control and have a negative urine pregnancy test on Day 1 before taking the dose.
- You must be willing to keep a stable cholesterol-lowering plan and diet (including your current medications) during the study.
- You must not have used certain cholesterol medicines after the base study, such as PCSK9 antibody injections, mipomersen, lomitapide, or specific related treatments (timing rules apply).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is a long-term follow-up for children and teens with familial hypercholesterolemia (a genetic condition causing very high cholesterol) who have already completed a previous study. It tests the safety and effectiveness of an investigational drug called lerodalcibep over a longer period.
This trial tests if a new medicine, lerodalcibep, can safely lower cholesterol in children ages 6 to 17 who have a genetic condition called heterozygous familial hypercholesterolemia (HeFH). It aims to help children whose cholesterol stays high despite taking standard cholesterol-lowering drugs.
This trial tests a new medication (QLC7401) for people with high cholesterol that is not well controlled by their current treatment. It aims to see if the drug can help lower LDL-C (bad cholesterol) levels and reduce the risk of heart problems.
This Phase 3 study tests whether JS002 alone can lower LDL “bad” cholesterol in people whose levels are still too high for their heart-risk level. It will also check how safe the treatment is, especially for heart and metabolic side effects.
This trial tests an experimental drug, QLC7401, for people with high LDL cholesterol that hasn't lowered enough with current treatments. It aims to see if the drug can help reduce cholesterol levels in patients who are already on stable cholesterol medication.
This study tests how a new drug moves through the body and affects cholesterol levels. It is for people with moderately high cholesterol who are otherwise healthy.
Hear when a new Familial Hypercholesterolemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.